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Echinococcosis is a zoonotic disease caused by the tapeworm Echinococcus.  The 
two most common species are E. granulosus and E. multilocularis.  They cause infections 
in humans called cystic echinococcosis (CE) and alveolar echinococcosis (AE), 
respectively. Due to current epidemiological trends, there is a growing need for a 
sensitive and specific assay that can distinguish between the two infections. The purpose 
of this research was to design a multiplex PCR assay for serum that will be able to 
simultaneously identify and distinguish between E. granulosus and E. multilocularis via 
high-resolution melting analysis (HRMA).  
A primer set was designed to amplify the mitochondrial ND5 gene of E. 
multilocularis and a previously designed and tested primer set was used to amplify a 
genomic repeat in E. granulosus known as EgG1 Hae III.  Human DNA was used as the 
positive internal control along with previously designed primers targeting the CFTR 
gene.  All templates and primer sets were combined into a multiplex reaction.  
Optimization was achieved by varying the primer concentrations to achieve equal 
amplification of all targets. 
Serial dilution of all three templates was carried out.  Each concentration of 
Echinococcus template was tested individually in combination with each concentration of 
control DNA to establish a limit of detection for each organism and an appropriate 
amount of control DNA to be used in the assay.
 iv 
 
To eliminate bias from the interpretation of results, 20 blind samples were tested. 
Each consisted of one of four concentrations of either Echinococcus template or water.  
Results were reported as E. multilocularis positive, E. granulosus positive or negative.  
The samples were de-blinded and compared to the results obtained.  Eighteen out of 20 
results were identified correctly.  The two samples that were not identified correctly were 
called negative, but had very low concentrations of either E. granulosus or E. 
multilocularis template.   
Further research should be conducted to find a more suitable positive control due 
to its preferential amplification.  However, this assay shows promise in its ability to 
detect very low levels of Echinococcus DNA and may have clinical use in the future.  
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INTRODUCTION 
There are nine species of Echinococcus, but only four are currently known to 
cause disease in humans.  The two most common are E. granulosus, which causes cystic 
echinococcosis (CE) and E. multilocularis, which causes alveolar echinococcosis (AE).1-4 
Both species require mammalian intermediate and definitive hosts to complete their 
lifecycles.  In the case of E. granulosus, a number of species can serve as intermediate 
hosts, but most are ungulates such as moose, elk, cattle and sheep.  The definitive hosts 
are canids such as wolves, foxes and dogs.  With E. multilocularis, intermediate hosts are 
rodents.  Definitive hosts are typically foxes, dogs and cats.  Humans can serve as 
aberrant intermediate hosts for both species.  When an intermediate host ingests an egg, it 
hatches in the stomach.  The hatched egg, known as an oncosphere, penetrates the wall of 
the small intestine and finds access to the vascular system, which transports it into organs 
such as the liver and lungs.  Although less common, they may be transported to other 
organs such as the brain, spleen or kidneys.5 Once the oncosphere has been deposited into 
an organ, it will develop into the metacestode stage.  The definitive host is infected when 
it ingests the organs of an infected intermediate host.  The parasite will develop into the 
mature tapeworm once it has reached the intestine of the definitive host.  The sexually 
mature tapeworm will produce eggs, which will be shed in the feces of the definitive 
host.  The intermediate host is typically infected by ingesting food that has been 
contaminated with the feces of an infected definitive host. 
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The major difference between E. granulosus and E. multilocularis lies in how 
they each develop inside an intermediate host.  For each, the metacestode stage involves 
the development of a germinal layer, from which the asexual production of multiple 
protoscoleces occurs via budding.  Thousands of protoscoleces can potentially be 
produced, each with the ability to develop into a mature adult worm.  When an E. 
granulosus oncosphere reaches its destination, it develops into the metacestode stage by 
producing a fluid-filled sac known as a hydatid cyst, which is why infection with E. 
granulosus is known as cystic echinococcosis or CE.  Cysts may occur singly or in 
clusters.  Daughter cysts may also develop inside primary cysts.  When intact, cysts are 
essentially walled off from the host.  Consequently, many infected individuals show no 
symptoms of infection and the spread of the parasite to different locations in the body is 
slow or nonexistent.  E. multilocularis metacestode germinal layers develop very 
differently from that of E. granulosus.  Instead of forming a fluid-filled cyst, the germinal 
layer forms solid protrusions that spread into surrounding tissues.  Germinal cells can 
also detach and spread to other organs in a metastatic fashion.  As the germinal layer 
proliferates, it produces small multiple vesicles, in which develop the protoscoleces.  The 
small vesicle makeup of the germinal layer causes it to take on an alveolar structure, 
which is why infection with E. multilocularis is known as alveolar echinococcosis or AE. 
The aberrant infection of humans with Echinococcus has become a major health 
concern worldwide.  CE is common in communities where sheep herding is the 
prominent profession.  Sheep ingest E. granulosus eggs by grazing in areas contaminated 
with feces of infected wild canids or herding dogs.  When sheep are slaughtered or die, 
the uncooked internal organs or offal of the sheep are often fed to the herding dogs, in 
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turn infecting the dogs with the parasite.  Shepherds can become infected by ingesting 
food or water that is contaminated with dog feces or by handling an infected host.  AE is 
more common in areas with large wild fox populations.  Foxes, dogs and cats are exposed 
when they consume an infected rodent.  Humans are infected in much the same way as 
they are with CE, by consuming contaminated food or water and by handling infected 
hosts.  Patients infected with CE may have no symptoms for many years.  Enlarging cysts 
can cause symptoms such as abdominal pain, a palpable hepatic mass and obstruction of 
the biliary duct.  If there are cysts present in the lungs, symptoms can include coughing, 
chest pain and asthma-like symptoms.  A serious complication of CE is anaphylactic 
shock associated with a leaking or ruptured cyst.  If not treated immediately, this can lead 
to rapid death.6 The symptoms of AE are often nonspecific and include weight loss and 
right upper quadrant pain due to enlarged liver.  Although AE infection proceeds like a 
slow-growing tumor, its course advances more quickly than that of CE.  The morbidity 
rate of patients with untreated AE is greater than 90% within 10 years of infection, 
whereas CE is usually asymptomatic unless the cyst is ruptured, causing an infection or 
anaphylactic reaction.1,4 
CE is present on all continents and is endemic to the Mediterranean, Middle East, 
central Asia, western China, South America and Africa.3-5,7-14 The areas of highest 
endemicity are South America and western China, with reports of infection rates of up to 
10% of the population.4,7 One area of note is the Tibetan Plateau in China where rates of 
infection are on the rise and up to 6.8% of the population is reported to be infected with 
CE.7,8 Neighboring central Asia has also reported infection rates as high as 3.4%.9 Both 
regions have high populations of herding and farming communities, increasing the risk of 
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infection.  The prevalence of infection in sheep and dogs of Tibetan communities has 
been reported to be up to 82% and 67%, respectively.7,10 Despite the successful 
implementation of control programs in a few Chinese provinces, prevalence remains high 
in several regions, including the Tibetan plateau.15 
AE is found almost exclusively in the northern hemisphere and is endemic to 
central Europe, China, central Asia, Eurasia and parts of North America.4,5,7-14,16-18 A few 
cases of AE have also been documented in Turkey and Iran.19,20 Recently, central Europe 
has seen an upswing in AE cases due to an unexpected surge in the population of red 
foxes, one of the primary hosts of E. multilocularis.  This increase in population is 
causing foxes to move into urban areas, posing an even greater risk to humans.  In 
addition to an increase in red foxes in central Europe, the population has spread to the 
North, West and especially to the East, now populating countries in the Baltic region and 
extending into central Asia. In the Naryn region of Kyrgyzstan, a recent study found a 
65% E. multilocularis infection rate in wild foxes and an 18% infection rate in domestic 
dogs.16,17,21 Human incidence has increased from a reported 0 – 3 cases in 1996 to more 
than 60 in 2011.9 Despite the sharp increase in cases in central Asia, the number of cases 
of AE in western China, and especially the Tibetan plateau, is much higher.  Tibetan 
foxes have been reported to have up to a 19% infection rate while up to 23% of dogs are 
infected.  One study reported a human infection rate as high as 6.2% in western China in 
2005, making it one of the most endemic regions in the world.8 
As shown, both CE and AE are endemic to central Asia and western China.  Co-
infection has even been reported in some patients on the Tibetan plateau.10,14,22 Both E. 
granulosus and E. multilocularis have been found in the fox populations of central Asia 
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and western China.7 The population surge and subsequent spread of the red fox 
throughout Europe and central Asia is resulting in an increase of both forms of 
echinococcosis in humans. It also raises the question as to whether CE will spread west 
into Europe through the migration of the red fox between these areas.  The World Health 
Organization recognizes both AE and CE as neglected tropical diseases.4 Continued 
neglect of echinococcosis in Europe and Asia may result in the increase of both CE and 
AE in these areas. 
 The sensitivity and specificity of current methods of diagnosis of both CE and AE 
are highly variable.  Currently, the most common method of diagnosis is by a 
combination of ultrasound and serologic or immunologic testing.  The gold standard for 
the diagnosis or confirmation of echinococcosis is ultrasound.1,23 It has a sensitivity of 
90% – 95%, is easy to perform and is relatively inexpensive. This makes portable 
ultrasound machines useful in population screening.  The hydatid cysts of CE appear as 
fluid-filled sacks.  Separation or inner folding of the hydatid membrane from the cyst 
wall can be seen as well as hydatid sand, which is composed of protoscoleces and 
hooklets of the parasites. AE lesions appear as irregular, tumor-like shapes that lack a 
well-defined boundary.  There is generally an area of central necrosis and there may be 
areas of calcification in the walls.1 Even with the high sensitivity of ultrasound, however, 
hydatid cysts may be misdiagnosed as things like pseudocysts if located in the pancreas.  
They may also be mistaken for lipomas, ovarian cysts or hepatic hematomas.  AE lesions 
can be misdiagnosed as cancerous tumors.1,23 Another type of imaging that has an even 
higher sensitivity than ultrasound at 95% - 100% is computed tomography or CT.20 
Although CT is useful for urban areas, it is impractical for more rural areas and for 
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population screening due to inaccessibility and cost.  Imaging, especially ultrasound, is 
generally confirmed by serological testing such as ELISA, indirect hemagglutination 
assay (IHA) or Immunoblot.  One option for the confirmation of CE is biopsy. Fluid can 
be aspirated from potential hydatid cysts to look for the presence of structures such as 
hooklets and protoscoleces.  However, there is a risk of causing leakage when the cyst 
wall is penetrated, which can cause anaphylaxis and a spread of the infection.1,6 
 ELISA is considered the most specific and sensitive of serologic tests for CE and 
AE.  It has been reported to have a sensitivity as high as 96.7% and a specificity of up to 
97.5%.23 Dot-ELISA used in field-testing in two studies showed a sensitivity and 
specificity of between 96% - 100% and 89.1% - 98%, respectively.1,23 IHA and 
immunoblot are also popular serologic tests for the diagnosis of AE and CE, although 
sensitivity and specificity are below that of ELISA.  Despite the success of some assays 
to accurately diagnose CE and AE, results are inconsistent.  Immunodiagnosis displays a 
high rate of false negative and false positive results.  It has been suggested that this is due 
to lack of standardization, especially when it comes to the source of antigen used.1  
Reiter-Owona et al. found that with both CE and AE, high antibody titers were necessary 
to achieve good detection.  They reported ELISA false negatives in 30.3% of patients, 
most of them coming from patients with low antibody titers.24 Another study reported 
15% false negatives by ELISA.25 These false negatives may be due in part to patients 
having intact cysts or cysts that are small, in extrahepatic locations or calcified.  A high 
rate of false positive results have also occurred from cross-reactions when patients are 
infected with other parasites, especially cestodes, and also in healthy subjects.23 Cross- 
reactivity between E. multilocularis and E. granulosus has also been reported due to the 
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similarity of their antigens.20,24,26 It has also been shown that sensitivity and specificity 
tend to be better in clinical settings as opposed to field settings, bringing into question the 
utility of serological tests for population screening.  
The most common source for antigens used in serological testing for CE is 
hydatid cyst fluid (HCF), which is obtained by extraction from surgically removed 
hydatid cysts.  HCF is a mixture of host and parasite.  Sensitivity using crude, unpurified 
HCF is good but specificity varies from 30% - 90%. Better results are obtained when 
specific antigens are purified from HCF.  One of the most studied antigens from E. 
granulosus is antigen 5 (Ag5), despite the fact that it has a high rate of cross-reactivity 
with healthy controls or non-CE patients.  Some studies show that purified and enriched 
Ag5 performs much better, but no large studies confirm this.23 Another highly studied 
antigen is antigen B (AgB), which is the main antigen found in HCF. It is highly 
immunogenic, which makes it a good candidate for diagnosing patients with lower titers 
of Ag5.  Although it is more specific than Ag5, it has high genetic variability.  The 
quality of AgB is important and probably explains the high variability in the sensitivity 
and specificity of AgB-based immune testing. It is specific for echinococcal infections 
but not very specific to E. granulosus as opposed to E. multilocularis, which produces its 
own AgB.1,23 Mamuti et al. found that a subunit of AgB obtained from each E. 
multilocularis and E. granulosus cross-reacted with both species on a Western blot. The 
E. multilocularis AgB subunit produced reactions in 81% of CE patients and 40.6% of 
AE patients.  The E. granulosus AgB subunit produced reactions in 86% of CE patients 
and 42% of AE patients.26 Given this level of cross-reactivity and lack of specificity, 
AgB based testing would not give reliable results in areas with co-endemic CE and AE.   
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Serologic tests achieve better results for AE than CE. Sensitivity and specificity 
for AE testing have been reported to be between 95 – 100%.  This is due to the nature of 
AE infection and the way it spreads.  Common antigens used to test for AE are Em2 and 
Em10, and occasionally Em18.  Some studies have reported that Em2 ELISAs, which are 
the most commonly used tests for AE, can differentiate between AE and CE, but Reiter-
Owana et al. showed that Em2 ELISA cross-reacted with CE in 23.5% of patients and 
that Em10 ELISA produced no cross-reactivity.  Although Em2-based testing is likely to 
identify AE infection, like serological CE tests, it would not be a reliable test to 
distinguish between AE and CE in areas where the population is at risk for both 
infections. 
Using serological tests to evaluate patients for continued disease or relapse after 
treatment is problematic.  Anti-CE antibodies may remain in serum for several years after 
treatment, making them unsuitable to evaluate possible relapse.  Although testing for the 
presence of antigens in serum instead of antibodies is much less sensitive and is rarely 
used for diagnosis, it has been suggested that it may be a better option in postsurgical 
monitoring since the presence of antigens is more conclusive than lingering antibodies.23 
However, for CE, detection of antigens even with a known active infection is too 
insensitive for antigen testing to be reliable.  Serological testing that distinguishes 
between subclasses of antibodies may help with distinguishing between active and past 
disease.  IgE, IgG1 and IgG4 have been shown to be associated with active infection.27 It 
has also been shown that igG2 is a good marker to indicate active infection and total IgG 
better for detection of relapse.28 Antibodies to E. granulosus proteins may remain in 
circulation for less time.  One of these proteins is P29, which only remained in circulation 
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in 10% of patients after three years vs. 25% for HCF antibodies.  However, P29 is not 
very reliable for initial diagnosis, so these results may be questionable.23 For AE, Em18 
or Em2 ELISA may be useful for postsurgical follow-up, since negative results are often 
achieved within four years of surgery and become positive again in cases of relapse.1 
However, given that Em2 can cross-react with CE, this may not be ideal in areas where a 
patient is in remission for AE, but has the possibility of acquiring CE. 
 Another option for the diagnosis of echinococcosis is by using polymerase chain 
reaction (PCR)-based assays.  PCR has been used for coprodiagnosis and differentiation 
of Echinococcus and other parasites in canid hosts with reports of 100% specificity.29,30 
Tissue and cystic samples have also been subjected to PCR in order identify the species 
via genotyping.  One study used PCR and restriction fragment length polymorphism 
(RFLP) method to identify dual infection of E. multilocularis and E. granulosus in 
animal hosts using tissue samples from infected definitive hosts.  The study was able to 
differentiate between the two species due to polymorphisms in the large ribosomal 
subunit in mitochondrial DNA. This was based on fragment length via electrophoresis 
after digestion of PCR products with enzymes.31 There has also been success in 
genotyping using different genomic or mitochondrial DNA targets and 
electrophoresis.29,30,32 Other studies have used PCR combined with high-resolution 
melting analysis (HRMA) in order to distinguish between different species of 
Echinococcus.33,34 These studies have almost exclusively used tissue samples from 
intermediate hosts or fecal samples from definitive hosts.  As previously stated, biopsy 
from cysts or the disruption of infected tissue may result in an anaphylactic reaction or 
the spread of the infection, making these testing methods impractical for routine use on 
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patients.   
Very few studies have used PCR-based methods on serum samples in order to 
detect Echinococcus and those that have show varying degrees of success.  One study 
attempted to detect E. granulosus in the serum of patients who had been confirmed 
positive for CE after surgical removal of cysts.32   It showed moderate success in 
detection with 75% sensitivity, with a specificity of 100%.  Another study used serum 
and urine samples from either surgically or ultrasonographically confirmed CE-positive 
patients in an attempt to diagnose CE.35 They found that only 50% of patients who were 
surgically confirmed to have CE tested positive via PCR when using serum and none of 
the patients who did not have surgery tested positive.  E. granulosus was also not 
detected in any of the urine samples via PCR.  Due to the nature of CE infection, it is not 
surprising that it is difficult to detect in serum.  Because it is walled off from the host, 
very little genetic material is likely to be circulating in a patient’s blood.  It is also 
noteworthy that in the study conducted by Chaya et al., the only patients who produced a 
positive result from serum were those that had cysts surgically removed.  There would 
certainly be disruption of the parasitic tissue during removal, making it more likely that it 
would be released into the patient, whereas those who did not have surgery tested 
negative 100% of the time.  Serum testing to detect E. multilocularis has almost 
exclusively used serologic testing since it is a reliable method with a high sensitivity.  
However, due to the growing problem of co-endmicity, it is becoming increasingly 
necessary to find a test that can distinguish between E. granulosus and E. multilocularis.  
Since serologic tests have shown high levels of cross-reactivity between the two 
organisms, a PCR-based test would be ideal to distinguish between them. The life cycle 
	 11	
of E. multilocularis means that there would likely be circulating parasitic DNA in the 
blood of patients.  It is likely, therefore, that it would not be difficult to detect AE 
infection with a PCR-based serum assay.  This is not the case with CE infection.  If there 
is any parasitic DNA circulating, it would probably be in very small amounts. The 
specificity of PCR assays used to genotype Echinococcus species is almost always near 
100%, which is the area that serologic tests are lacking.  Where PCR-based assays are 
currently lacking, especially when it comes to E. granulosus, is sensitivity. 
 In order to design an assay that can detect low levels of circulating DNA, it is 
important to choose an appropriate genetic target.  Ideally, this would be a target that 
occurs in many copies throughout the genome of the parasite.  For this reason, 
mitochondrial DNA, at between 1000 – 2000 copies per cell, is almost always the target 
when genotyping Echinococcus species.36 Mitochondrial genes that are the most 
conserved and which have been targeted most often include NADH dehydrogenase 
subunits one and five (ND1, ND5), cytochrome c oxidase subunit one (COX1) and the 
12S subunit of the mitochondrial ribosome.29,32,35,37 While the targeting of a 
mitochondrial gene would most likely be adequate for the detection of E. multilocularis, 
that may not be the case for E. granulosus, as shown by the negative results found in the 
study conducted by Chaya et al.  Another possible target is a 269 basepair-long genomic 
repeat known as EgG1 Hae III.30 This repeat is estimated to occur approximately 6900 
times in the E. granulosus genome, which is estimated to be 150 million basepairs long.  
This means there is a greater chance of detecting this repeat than there would be of 
detecting mitochondrial DNA from the same amount of circulating parasitic cells. 
 In addition to choosing an appropriate target, it is essential to have a simple assay 
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design if it is to be useful in field settings.  Because infected individuals are often in rural 
areas, designing an assay that involved the need for a high skill level or expensive and 
complicated equipment would be impractical.  This would make it wise to eliminate 
methods that involved the need for electrophoresis or specialized probes.  The simplest 
method would be to use an intercalating dye and perform genotyping based on the 
differences in melting temperatures.  To simplify the testing process as much as possible, 
it is also essential that the assay be able to detect and differentiate between E. granulosus 
and E. multilocularis simultaneously, which would require a multiplex design.  The 
advantage to using a molecular assay to detect Echinococcus is that specificity is nearly 
100%; the challenge is to increase the sensitivity.  While efforts continue to make 
serological testing more specific, the answer to finding an effective means of diagnosis 
and monitoring of AE and CE may not lie with serological testing, but with a more 
sensitive PCR-based assay.		
MATERIALS AND METHODS 
The first phase of the research plan involved choosing appropriate genetic targets 
and designing primer pairs that would successfully amplify the targets using real-time 
PCR.  The amplified sequences also needed to have different and distinct melting 
temperatures or Tm, which is the temperature at which half the double-stranded DNA has 
become denatured into single strands. These different melting temperatures would be 
used to identify the targets in a multiplex reaction using high-resolution melting analysis 
(HRMA). Targets for E. multilocularis and E. granulosus were chosen from regions of 
mitochondrial or genomic DNA that would be unique to each organism.  Candidate 
targets were checked in BLAST® (http://blast.ncbi.nlm.nih.gov/Blast.cgi) for similarity 
between the two organisms as well as human DNA.  The chosen targets were found to 
have no matches in the human genome or that of the other parasite.  Due to lack of 
available parasitic tissue or extracted DNA, gBlocks® Gene Fragments (Integrated DNA 
Technologies) synthetic DNA was used as parasite DNA.  Targets were designed using 
the published sequences in GenBank® (http://www.ncbi.nlm.nih.gov/genbank/) or from 
previously conducted research.30 Primers were synthesized by the DNA/Peptide Facility, 
part of the Health Sciences Center Cores at the University of Utah. Target sequences and 
primers were received lyophilized. After reconsititution, concentrations were determined 
and adjusted with the NanoDrop 2000 spectrophotometer (Thermo Scientific) and 
LabVIEW 7.1 (National Instruments) designed program CHECKOLIGO version 4.  All
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primer candidates were tested individually via PCR to determine the success of target 
amplification and suitable melting temperature.  After the chosen targets and the primer 
pairs were individually tested, the three sets of primers were checked for the possibility 
of primer dimer formation during the multiplex reaction using Multiple Primer Analyzer 
software (ThermoFisher Scientific).  Primer dimer formation was found to be unlikely or 
low-grade, which confirmed the chosen primers as suitable for the multiplex reaction. 
The second phase consisted of all primer pairs and template DNA being combined 
into a multiplex reaction.  In order to optimize the multiplex reaction, template DNA for 
each organism and the control were each added at 14,000 copies/µl. Primer 
concentrations were adjusted to achieve an optimized amplification of all targets.  All 
amplicon melting conducted in preliminary primer testing and multiplex optimization 
was done on the LightCycler® 2.0 (Roche).   
The third phase was to systematically reduce the concentration of template copies 
of each organism in order to establish a limit of detection. This was accomplished by 
tenfold serial dilution of template copies of E. multilocularis and E. granulosus.  Each 
concentration was tested individually in combination with the control DNA.  The control 
DNA template was then diluted in the same manner to establish if high copy numbers of 
control DNA would wash out low-level detection of either or both organisms.  The goal 
of varying the quantity of control DNA was to find a concentration that would be 
sufficient to serve as a reliable internal control but not so high as to prevent the detection 
of low levels of E. multilocularis or E. granulosus.  HRMA was done on all reactions 
conducted in the dilution series on the HR-1 analyzer (BioFire Defense). 
The fourth phase was to conduct 20 blind tests. When the amount of template 
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DNA in each reaction was known and specific peaks were being looked for, there was a 
possibility that it could bias the interpretations of the HRMA results.  The blind tests 
were conducted to eliminate that bias.  Each randomly chosen template DNA sample was 
de-identified and assigned a number 1 – 20.  Each contained 14 copies/µl, 140 copies/µl, 
1400 copies/µl or 14,000 copies/µl of E. multilocularis or E. granulosus DNA templates 
or water.  Each was tested in triplicate.  Samples 1 – 10 were tested with control DNA at 
140 copies/µl.  Samples 11 – 20 were tested with control DNA at 14 copies/µl.  Samples 
1 – 10 with ambiguous results were repeated singly with control DNA reduced to 14 
copies/µl.  Samples 11 – 20 with ambiguous results were repeated singly with no control 
DNA added. The PCR reaction and HRMA were conducted and results were reported as 
positive for E. multilocularis, positive for E. granulosus or negative (only control DNA 
present).  Some results were also reported as positive or negative, but with a desire to  
retest due to ambiguous results. 
Primer Design 
E. multilocularis 
 The target for E. multilocularis was the mitochondrial gene, ND5, which has 
distinct differences from the ND5 gene of E. granulosus. Three primer sets were 
designed using the Primer3 software at http://bioinfo.ut.ee/primer3-0.4.0/. Primer set 1, 
with a forward sequence of 5’-TGGTAGTGGTGGTTCTCAAGC-3’ and a reverse 
sequence of 5’-AACCAAGGACCACAGCAAAC-3’, produced a 94-basepair amplicon 
with a melting temperature of 79.3°C.  Primer set 2, with a forward sequence of 5’-GGG 
CCCCTACTCCAGTTAGT-3’ and a reverse sequence of 5’-ACCAAACACCAGCAGC 
AACT-3’, produced a 63-basepair amplicon with a melting temperature of 81.3°C. 
	 16	
Primer set 3, with a forward sequence of 5’-GTTAGTATCGTCTCGATTTG-3’ and a 
reverse sequence of 5’-GGAAATACCCCACTATCC-3’ produced an 81-basepair 
amplicon with a melting temperature of 79.1°C.  Primer set 1 was chosen for inclusion in 
the multiplex reaction due to its melting temperature and strong performance during  
initial testing (Figure 1). 
E. granulosus 
The target for E. granulosus was a repeated genomic sequence known as EgG1 
Hae III.  This repeat is estimated to constitute approximately 1.25% of the E. granulosus 
genome, making it a more abundant target than mitochondrial DNA sequences. A primer 
set (EGG1) designed by Abbasi et al., with a forward sequence of 5’-GAATGCAAGCA 
GCAGATG-3’ and a reverse sequence of 5’-GAGATGAGTGAGAAGGAGTG-3’, was 
tested and performed well.30 It produces a 133-basepair amplicon with a melting  
temperature of 85.8°C (Figure 1).   
Control DNA 
Human DNA from a single donor and previously designed primers targeting 
exons 3 and 10 on the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
were tested for use as internal controls based on their projected melting temperatures.38,39 
Primers targeting exon 3, with a forward sequence of 5’-TTTGCACATGCAACTTATTG 
G-3’ and a reverse sequence of 5’-CAAATGAGATCCTTACCCCTAAA-3’, produced a 
160-basepair amplicon with a melting temperature of 82.2°C.  Primers targeting exon 10, 
with a forward sequence of 5’-ACTTCTAATGGTGATTATGGG-3’ and a reverse 
sequence of 5’-ACATAGTTTCTTACCTCTTC-3’, produced a 201- basepair amplicon 
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   Figure 1.  All templates and primer sets tested for E. multilocularis, E. granulosus and    






















E. multilocularis ND5 sequence: Primer set 1, Primer set 2, Primer set 3 
E. granulosus EgG1 Hae III sequence: 
 
CFTR exon 10 sequence: 
5’- 
5’- 
         CFTR exon 3 sequence: 
 
5’-TTTGCAGATGCAACTTATTGGTCCCACTTTTTATTCTTTTGCAGAGAATGGGATAGAG 
   AGCTGGCTTCAAAGAAAAATCCTAAACTCATTAATGCCCTTCGGCGATGTTTTTTCTG 
   GAGATTTATGTTCTATGGAATCTTTTTATATTTAGGGGTAAGGATCTCATTTG-3’ 	
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with a melting temperature of 82.3°C.  Both performed well in preliminary testing, but 
the second primer set performed better in multiplex testing, so it was chosen for use in  
the multiplex reaction (Figure 1). 
Multiplex Optimization 
 In order to optimize the multiplex reaction, template DNA for each organism and 
the control were added in equal amounts at 14,000 copies/µl.  All templates and primer 
pairs were individually evaluated with forward and reverse primer concentrations at 0.5 
µmol/L.  Therefore, the multiplex reaction was first tested with all primer concentrations 
set to 0.5 µmol/L.  Optimized amplification of all targets was achieved by making 
adjustments to primer concentrations.  The goal was to achieve strong distinction 
between melting peaks and avoid unbalanced fluorescence intensity between the three 
peaks.  Primer concentrations producing the best results were E. multilocularis at 0.1  
µmol/L, Control at 0.5 µmol/L and E. granulosus at 0.25 µmol/L. 
PCR Mixture 
The multiplex reaction mixture in 10 µl volumes with optimized primer 
concentrations included 0.1 µmol/L forward and reverse E. multilocularis primers, 0.5 
µmol/L forward and reverse control primers, 0.25 µmol/L forward and reverse E. 
granulosus primers, 0.4 U KlenTaq1™ (Ab Peptides), 3 mmol/L MgCl2, 50 mmol/L Tris 
(pH 8.3) and 2.5 mg/L BSA (Sigma).  Also included were 1X LCGreen® Plus dye 
(BioFire Defense), 0.2 mmol/L each deoxynucleoside triphosphate and 14,000 copies/µl 
of each template DNA. The multiplex reaction mixture was used for all reactions in the 
dilution series and blind testing with varying numbers of template DNA added.  
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Reactions for individual primer testing used the same reaction mixture except only primer  
sets being tested were included and at a concentration of 0.5 µmol/L.  
PCR Amplification and Preliminary Melting Protocol 
PCR was performed in closed capillary tubes in a LightCycler® 2.0 with an initial 
denaturation of 95°C for 2 min, followed by 35 cycles of denaturation at 95°C for 0 s, 
annealing at 58°C for 4 s and extension at 72°C for 4 s.  Transition rate between 
temperatures was 20°C/s and fluorescence was acquired at the end of each extension step.  
Melting for preliminary primer set and multiplex optimization was achieved by 
denaturing PCR products at 95°C for 0 s, annealing at 70°C for 10 s, then raising the 
temperature to 95°C at a transition rate of 0.2°C/s with continuous fluorescence 
monitoring. 
Dilution Protocol 
 Template DNA for E. granulosus, E. multilocularis and control were each serially 
diluted from 14,000 copies/µl to 1400 copies/µl, 140 copies/µl and 14 copies/µl.  E. 
granulosus and E. multilocularis templates were tested individually at each of the four 
concentrations with each of the four concentrations of the control DNA.  HRMA was  
done on each reaction with 1400 copies/µl or less of control DNA.  
High-Resolution Melting 
Following amplification on the LightCycler® II, the multiplex reaction with final 
primer concentrations and each reaction in the dilution series was subjected to high-
resolution melting in the HR-1 analyzer.  Melting was started at 65°C and the 
temperature was increased to 90°C at a transition rate of 0.3°C/s.  LED power was  
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automatically adjusted to 90% fluorescence. 
Data Analysis 
 High-resolution melts were analyzed with MeltingWizard6 software (University 
of Utah).  Each melt was converted into a negative first derivative curve and displayed as 
the negative first derivative of fluorescence with respect to temperature vs. temperature in 
the form of melting peaks.  Each melting peak plot from the dilution series and blind 
samples was compared to that of the multiplex reaction to determine if there was 
detectable amplification of either or both organisms or the control DNA. 	
RESULTS 
After combining the three DNA templates and the chosen primer sets into a 
multiplex reaction and comparing melting curves obtained on the HR-1, the melting 
temperatures increased for all three template/primer pairs as compared to when they were 
tested individually.  E. multilocularis increased from 79.3°C to 80.2°C, E. granulosus 
increased from 85.8°C to 86.7°C and the control increased from 82.3°C to 82.8°C.  When 
the reactions included either E. multilocularis or E. granulosus and control templates, 
melting temperatures decreased back down close to original melting temperatures when 
each template was evaluated alone on the LightCycler 2.0 (Figure 2). These observations 
were used during blind testing to determine if template DNA for either organism was 
present. 
When templates of E. multilocularis or E. granulosus were used in 1400 
copies/µl, 140 copies/µl and 14 copies/µl concentrations, it became quickly apparent that 
leaving the control DNA template concentration at 14,000 copies/µl would wash out any 
low-level detection of E. multilocularis or E. granulosus.  Concentrations of 1400 
copies/µl, 140 copies/µl and 14 copies/µl of the control DNA were tested with each of the 
four concentrations of E. multilocularis and E. granulosus template and HRMA was 
conducted.	 
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Figure 2.  Illustrates the shift in melting temperatures of the three DNA templates when 
run alone vs. in combination. (A) The melting peak of E. multilocularis when run alone. 
(B) The melting peak of E. granulosus when run alone. (C) The melting peak of the 
control DNA when run alone. (D) The melting peaks of E. multilocularis and the control 
DNA when run together.  (E) The melting peaks of E. granulosus and the control DNA 
when run together.  (F) The melting peaks of all three templates when combined in a 
multiplex reaction.  A – C produced on the LightCycler 2.0; D – F produced on the HR-1. 
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Dilution Series Results 
Control DNA at 1400 copies/µl 
With control DNA concentrations at 1400 copies/µl, there was no detection of E. 
multilocularis or E. granulosus at 14 copies/µl.  When copy numbers of E. multilocularis 
and E. granulosus were increased to 140 copies/µl, there was only very weak detection of 
both.  When copy numbers of E. multilocularis and E. granulosus were increased to 1400 
copies/µl, there was positive detection of both, but the control DNA peak was much 
higher than that of either.  When E. multilocularis concentration was increased to 14,000 
copies/µl, there was clear detection, but the fluorescence of the control DNA peak was 
still much higher.  With E. granulosus at 14,000 copies/µl, its peak and the control DNA 
peak were nearly equal in height (Figure 3).  
Control DNA at 140 copies/µl 
 With control DNA concentrations at 140 copies/µl, there was weak positive 
detection of both E. multilocularis and E. granulosus at concentrations of 14 copies/µl.  
There was positive detection of E. multilocularis when increased to 140 copies/µl, but 
with a much lower peak than that of the control.  There was positive detection of E. 
granulosus at 140 copies/µl and with only a slightly higher control peak.  When copy 
numbers of E. multilocularis were increased to 1400 copies/µl, there was strong positive 
detection, but with a slightly lower melting peak than the control.  There was also strong 
positive detection of E. granulosus at 1400 copies/µl, with its melting peak and that of 
the control at near equal heights.  When copy numbers of E. multilocularis were 
increased to 14,000 copies/µl, there was strong positive detection with its melting peak  
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Figure 3.  High-resolution melting curves from the dilution series with the control DNA 
template concentration at 1400 copies/µl.  (A) E. multilocularis at 14 copies/µl.  (B) E. 
granulosus at 14 copies/µl. (C) E. multilocularis at 140 copies/µl.  (D) E. multilocularis 
at 140 copies/µl.  (E) E. multilocularis at 1400 copies/µl. (F) E. granulosus at 1400 
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nearly equal to that of the control.  There was also strong positive detection of E. 
granulosus at 14,000 copies/µl and with a significantly higher melting peak than that of 
the control (Figure 4). 
Control DNA at 14 copies/µl 
 With control DNA concentrations at 14 copies/µl, there was positive detection of 
both E. multilocularis and E. granulosus also at 14 copies/µl.  Both had melting peaks 
near equal in height to that of the control.  When copy numbers of E. multilocularis and 
E. granulosus were increased to 140 copies/µl, both showed strong positive detection 
with melting peaks exceeding the height of the control.  When copy numbers of E. 
multilocularis and E. granulosus were increased to 1400 copies/µl, both showed strong 
positive detection with significantly higher melting peaks than that of the control.  When 
E. multilocularis was increased to 14,000 copies/µl, it showed strong positive detection, 
also with a significantly higher melting peak than that of the control.  When E. 
granulosus was increased to 14,000 copies/µl, it showed strong positive detection, but no 
control DNA amplification is evident (Figure 5). 
Blind Test Results 
 Out of the 20 blind samples, 11 were retested with no control or with a reduced 
concentration of control due to ambiguous results.  Even with the retests conducted with 
reduced control template concentration, blind samples 6 and 18 were called negative, but 
with a desire to retest due to a possibility of a weak positive for E. granulosus or E. 
multilocularis, respectively.  Sample 6 was called negative, but was actually positive for  
E. granulosus, at a concentration of 14 copies/µl.  Sample 18 was called negative, which  
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Figure 4.  High-resolution melting curves from the dilution series with the control DNA 
template concentration at 140 copies/µl.  (A) E. multilocularis at 14 copies/µl.  (B) E. 
granulosus at 14 copies/µl. (C) E. multilocularis at 140 copies/µl.  (D) E. multilocularis 
at 140 copies/µl.  (E) E. multilocularis at 1400 copies/µl. (F) E. granulosus at 1400 
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Figure 5.  High-resolution melting curves from the dilution series with the control DNA 
template concentration at 14 copies/µl.  (A) E. multilocularis at 14 copies/µl.  (B) E. 
granulosus at 14 copies/µl. (C) E. multilocularis at 140 copies/µl.  (D) E. multilocularis 
at 140 copies/µl.  (E) E. multilocularis at 1400 copies/µl. (F) E. granulosus at 1400 
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was correct.  Sample 19 was called negative, but was actually positive for E. 
multilocularis at a concentration of 14 copies/µl.  All other samples were identified  
correctly (Table 1, Figure 6). 
Ambiguous results 
 The original HRMA from blind sample 2 produced what looked like a peak at 
both the E. multilocularis and E. granulosus positions.  E. multilocularis positivity was 
sure, but E. granulosus was in question.  The sample was repeated with control DNA 
concentration reduced to 14 copies/µl.  The resulting HRMA curve showed a peak at the 
E. multilocularis position and one at the control position (Figure 6, parts B1 and B2).  
The original HRMA curve from blind sample 3 showed a possible weak E. granulosus 
positive. When repeated with control DNA concentration reduced to 14 copies/µl, the 
resulting HRMA curve showed a peak at the E. granulosus position and one at the control 
position (Figure 6, parts C1 and C2).  The original HRMA curve from blind sample 4 
showed possible positives for both E. multilocularis and E. granulosus with some 
inconsistency between replicates.  When repeated with the control DNA concentration 
reduced to 14 copies/µl, the resulting HRMA curve showed a peak at the E. 
multilocularis position and one at the control position (Figure 6, parts D1 and D2).  The 
original HRMA curve from blind sample 6 showed a possible weak positive for E. 
granulosus.  When repeated with control DNA concentration reduced to 14 copies/µl, the 
resulting HRMA curve showed a very small peak at the E. granulosus position and one at 
the control position along with an unknown peak at 80.2°C (Figure 6, parts F1 and F2).  
The original HRMA curve from blind sample 7 showed a possible weak positive for both 
E. multilocularis and E. granulosus.  When repeated with the control DNA reduced to 14  
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Table 1.  Test results of each blind sample are represented by check marks in the E.m. +, 
E.g. + or Negative columns.  E.m.: E. multilocularis, E.g.: E. granulosus; starred results 





Blind 1 ✓	 	 	 	 E.m. 14,000 Yes 
Blind 2 ✓	 	 	 ✓	 E.m. 140 Yes 
Blind 3 	 ✓	 	 ✓	 E.g. 14 Yes 
Blind 4 ✓	 	 	 ✓	 E.m. 14 Yes 
Blind 5 	 ✓	 	 	 E.g. 14,000 Yes 
Blind 6 	 	 ✓* ✓	 E.g. 14 No 
Blind 7 	 ✓	 	 ✓	 E.g. 14 Yes 
Blind 8 ✓	 	 	 ✓	 E.m. 1400 Yes 
Blind 9 ✓	 	 	 	 E.m. 140 Yes 
Blind 10 	 ✓	 	 	 E.g. 140 Yes 
Blind 11 ✓	 	 	 ✓	 E.m. 140 Yes 
Blind 12 	 ✓	 	 	 E.g. 1400 Yes 
Blind 13 ✓	 	 	 	 E.m. 1400 Yes 
Blind 14 	 ✓	 	 ✓	 E.g. 140 Yes 
Blind 15 	 	 ✓	 	 H2O Yes 
Blind 16 	 ✓	 	 	 E.g. 140 Yes 
Blind 17 ✓	 	 	 	 E.m. 140 Yes 
Blind 18 	 	 ✓* ✓	 H2O Yes 
Blind 19 	 	 ✓	 ✓	 E.m. 14 No 
Blind 20 	 ✓	 	 ✓	 E.g. 1400 Yes 
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Figure 6.  High-resolution melting curves from the blind samples.  (A) Blind sample 1.  
(B1) Blind sample 2.  (B2) Blind sample 2 repeat. (C1) Blind sample 3.  (C2) Blind 
sample 3 repeat. (D1) Blind sample 4.  (D2) Blind sample 4 repeat.  (E) Blind sample 5.  
(F1) Blind sample 6.  (F2) Blind sample 6 repeat.  (G1) Blind sample 7.  (G2) Blind 
sample 7 repeat.  (H1) Blind sample 8.  (H2) Blind sample 8 repeat.  (I) Blind sample 9.  
(J) Blind sample 10.  (K1) Blind sample 11.  (K2) Blind sample 11 repeat.  (L) Blind 
sample 12.  (M) Blind sample 13.  (N1) Blind sample 14.  (N2) Blind sample 14 repeat.  
(O) Blind sample 15.  (P) Blind sample 16.  (Q) Blind sample 17.  (R1) Blind sample 18.  
(R2) Blind sample 18 repeat.  (S1) Blind sample 19.  (S2) Blind sample repeat.  (T1) 
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copies/µl, the resulting HRMA curve showed a peak at the E. granulosus position and 
one at the control position along with an unknown peak at 81.2°C (Figure 6, parts G1 and 
G2).  The original HRMA curve from blind sample 8 showed a strong positive for E. 
multilocularis, but a possible weak positive for E. granulosus.  When repeated with the 
control DNA reduced to 14copies/µl, the resulting HRMA curve showed a peak at the E. 
multilocularis position and one at the control position along with a small, unknown peak 
at 85°C (Figure 6, parts H1 and H2).  The original HRMA curve from blind sample 11 
showed a strong positive for E. multilocularis, but a possible weak positive for E. 
granulosus.  When repeated with no control DNA present, the resulting HRMA curve 
showed a peak at the E. multilocularis position and a very small peak at the control 
position despite the fact that no control DNA template was added (Figure 6, parts K1 and 
K2).  The original HRMA curve from blind sample 14 showed a possible weak positive 
for E. granulosus.  When repeated with no control DNA present, the resulting HRMA 
curve showed a peak at the E. granulosus position along with an unknown peak at 78.7°C 
(Figure 6, parts N1 and N2).  The original HRMA curve from blind sample 18 showed a 
probable negative, but with a possible weak positive of E. multilocularis.  When repeated 
with no control DNA present, the resulting HRMA curve showed a peak at 79.8°C, which 
is a higher melting temperature than expected when E. multilocularis is run alone (Figure 
6, parts R1 and R2).  The original HRMA curve from blind sample 19 showed a probable 
negative, but possible weak positives for E. multilocularis and E. granulosus.  When 
repeated with no control DNA present, the resulting HRMA curve showed a peak at 
80°C, which a higher melting temperature than expected when E. multilocularis is run 
alone (Figure 6, parts S1 and S2).  The original HRMA curve from blind sample 20 
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showed possible positives for both E. multilocularis and E. granulosus with some 
inconsistency between replicates.  When repeated with no control DNA present, the 
resulting HRMA curve showed a peak at the E. granulosus position along with an 
unknown peak at 78.3° (Figure 6, parts T1 and T2). 
DISCUSSION 
 Currently, no other PCR-based assay exists that is designed to test for both E. 
multilocularis and E. granulosus concurrently using human serum or plasma.  The need 
for an assay of this nature lies in the current epidemiological trends occurring with both 
CE and AE. In areas that are co-endemic, a reliable means of differentiation is needed.  
The limitations of this research lie in the source for genetic materials used.  Genetic 
sequences used for both E. granulosus and E. multilocularis were synthetic DNA based 
on the published genetic sequences of these organisms.  No actual parasitic material or 
extracted DNA was available for use in this project.  There were also no patient 
specimens tested in order to validate the assay for possible clinical use.  The hope is that 
further research can be conducted on this method when parasitic DNA and patient 
samples become available for testing.  The goal of this project was to establish a limit of 
detection for each organism.  If there are circulating cells or cell-free DNA present in the 
blood of infected individuals, it is likely to be present in very small amounts, which 
makes it essential that any assay attempting to detect it be sensitive.   
One challenge that was not foreseen when beginning this research was how much 
the control DNA and the primer set designed to amplify it might affect the detection 
levels of the E. multilocularis and E. granulosus DNA.  The reasons behind choosing 
human DNA as the positive control included the lack of any similar sequences to that of 
E. multilocularis or E. granulosus and the easy access to extracted human genomic DNA. 
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Another reason for its use is the fact that one would expect to find it in human serum or 
plasma, which would make spiking it into the PCR reaction unnecessary when used on 
clinical samples.  There was a significant difference between the melting temperatures of 
E. multilocularis and E. granulosus amplicons, leaving room for a melting peak in 
between them.  Both of the CFTR primer-set candidates were chosen because the melting 
temperature of the products would fall right in between the melting temperatures of the 
two parasites.  However, when the CFTR3 and CFTR10 primer sets were initially tested 
by other researchers, the PCR reaction mixture contained MgCl2 at a concentration of 2 
mmol/L when all primer sets for E. multilocularis and E. granulosus had been tested at a 
MgCl2 concentration of 3 mmol/L.38,39 Because of this, primer sets were then retested 
with MgCl2 concentration reduced to 2 mmol/L.  Although the primer set for E. 
multilocularis seemed to perform well, there was no amplification of the E. granulosus 
template at the lower MgCl2 concentration.  Because the CFTR primer sets also 
performed well with 3 mmol/L MgCl2, that is the concentration that was used in the PCR 
mixture for this project despite the fact that it would decrease stringency for the control 
DNA.  It is clear when looking at the HRM melting curves throughout the dilution series 
and blind samples that there seemed to be preferential amplification of the control DNA 
over that of the other two templates (Figure 3, Figure 4, Figure 5, Figure 6).  The E. 
multilocularis template concentration needed to be at approximately 100 times that of the 
control DNA before its fluorescence matched that of the control DNA.  E. granulosus 
was less dramatic, but still needed a concentration of approximately ten times that of the 
control DNA in order to reach equal fluorescence.  Although the concentration of primers 
was highest for the control DNA, which could also help explain its preferential 
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amplification, the multiplex reaction did not have good results when the control DNA 
primer concentration was decreased.  Therefore, it would be worth finding a primer set 
that performed better at 3 mmol/L MgCl2 and not so well at 2 mmol/L MgCl2.  This 
might help balance the amplification of the templates and eliminate the preferential 
amplification of the control DNA template. 
The reason that half the blind samples were tested with 140 copies/µl and the 
other half with 14 copies/µl of control DNA template was partially to demonstrate that 
the control DNA was being preferentially amplified and partially because cleaner HRMA 
curves were produced when control DNA template concentration was at 140 copies/µl.  
Despite the higher probability of detecting E. multilocularis or E. granulosus with control 
DNA template at 14 copies/µl, there was a possibility that there would be fewer 
ambiguous results when evaluating cleaner melting curves.  This, however, was not the 
case.  Most of the ambiguous results produced for blind samples 1 – 10 were because 
very small peaks at the positions of E. multilocularis and E. granulosus were produced 
that indicated possible weak positives.  Most of the ambiguous results produced for blind 
samples 11 – 20 were because there was more noise present on the HRM curve.  This is 
most attributable to small, aberrant peaks that made positive identification of peaks at the 
E. multilocularis and E. granulosus positions more difficult.  In the case of all repeated 
blind samples, results almost always became less ambiguous when control DNA 
concentrations were decreased or eliminated from the reaction. 
The results of the dilution series and blind samples demonstrate a need to look for 
a different positive control to include in the assay.  Using human DNA as a positive 
control may be inadvisable in this assay for a few reasons.  One reason is that given the 
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abundance of human DNA in the laboratory environment, it makes contamination of the 
reaction more likely than if a nonhuman source was used.  Some of the HRM curves from 
the dilution series and the blind samples show contamination of the no template controls 
(Figure 2Results, part H; Figure 3Results, part E; Figure 4Results, part H, Figure 
5Results, part K2).  It has been shown in this project that an increase in the amount of 
human DNA can easily wash out low-level detection of either parasite.  Therefore, an 
increase in human DNA template due to contamination could be detrimental to the 
success of the assay.  Another reason to not use human DNA as the control is that it 
limits the kind of sample that can be used in the assay.  If peripheral blood is collected for 
testing, the only acceptable sample for this assay would be to use plasma, which is the 
liquid portion of anti-coagulated blood.  Serum would be unacceptable as it is derived 
from coagulated blood, which has a much higher amount of cell-free DNA due to the 
white blood cell lysis that occurs during the clotting process.  Research conducted by Lee 
et al. compared the amount of cell-free DNA present in plasma vs. serum samples 
between 18 healthy donors.40 They found that only two out of the 18 plasma samples 
were positive for cell-free DNA.  The two positive samples each had approximately 40 
copies/mL present.  However, all 18 serum samples had high concentrations of cell-free 
DNA present with a mean of 20,000 copies/mL.  If serum samples were used to test for 
E. multilocularis and E. granulosus with the use of human DNA as a control, there would 
be so much human DNA present that detection of either parasite would be extremely 
unlikely.  The amount of human DNA present could also pose a problem with improperly 
collected plasma specimens.  If venipuncture was not performed correctly, it could result 
in cell lysis, which would increase the amount of human DNA in the plasma sample.  For 
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these reasons, it would be advisable to look for a alternative positive control.  A 
possibility would be plant-based DNA, which would be unlikely to have any similarity to 
the genomes of E. multilocularis or E. granulosus. 
Regardless of the positive control used, one does need to be included and even if 
it is not preferentially amplified, it could still wash out low-level detection of either 
organism.  This research shows that it is possible to detect both organisms down to 14 
copies/µl, although not all of the time.  Three of the blind samples contained E. 
granulosus at 14 copies/µl, two of which were called positive. Two of the blind samples 
contained E. multilocularis at 14 copies/µl, one of which was called positive.  Trying to 
detect anything less than 14 copies/µl would likely produce negative results.  This raises 
the question of how many parasitic cells or how much cell-free DNA needs to be present 
in blood in order to detect it via PCR.  The E. multilocularis ND5 gene is a mitochondrial 
gene.  This means there will be at least 1000 copies of that gene in one cell.  The E. 
granulosus EgG1 Hae III genomic repeat is estimated to occur 6900 times in one cell. 
According to the American Red Cross, the average adult has approximately 10 pints of 
blood in his or her body.41 That equals approximately 4732 mL.  If circulating parasitic 
cells are intact, the genetic contents of one cell would be more than sufficient to detect it 
via PCR.  However, if 5 mL of blood were drawn from a patient, in order to get an 
average of one cell in that 5 mL, there would need to be 946 cells in circulation.  In the 
case of E. multilocularis, this may be possible, but it would be unlikely with E. 
granulosus.  If, however, the cells were not intact and had undergone apoptosis, there 
would be cell-free DNA circulating.  In that case, there would need to be approximately 
14,000 copies of the E. multilocularis ND5 gene or the E. granulosus EgG1 Hae III 
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repeat in circulation for there to be an average of 15 copies in each 5mL of blood.  In the 
case of E. multilocularis, this would require the contents of 14 cells to be circulating.  For 
E. granulosus, it would only need to be two cells.  Given these estimates, it seems 
probable that E. multilocularis could be easily detected in serum or plasma via PCR and 
at least possible that E. granulosus could be detected despite the nature of its lifecycle, 
especially during the initial phase of infection before any cysts have formed.  If there are 
intact parasitic cells present, it may be slightly more advantageous to use serum rather 
than plasma.  Whole cells would be more likely to rupture and release their contents 
during the clotting process required for serum collection, making detection easier than if 
only cell-free DNA were present.  It would also be necessary to concentrate the serum or 
plasma in order to be able to use the small volume of specimen required in each reaction.  
However, even with concentration, the more serum used in the reaction, the more 
probable it would be to detect any small amounts of template that may be present.  
During this project, each 10 µl reaction in the dilution series and blind tests contained 1 
µl of forward and reverse primers, 1 µl of control template, 1 µl of either E. 
multilocularis or E. granulosus template, 5 µl of water and 2 µl of reaction mixture (see 
Materials and Methods).  Sensitivity could potentially be increased by eliminating the 
water and using 6 µl of serum instead.  
Given the need for a laboratory setting and an analyzer, this method would not be 
useful for field-testing at this time, especially in rural areas, but innovations in molecular 
methods could make it possible in the future.  Millions of people worldwide are at risk 
for infection of either or both parasites.  Because of the co-endemicity occurring in 
central Asia and China, there is an increasing need for an assay that can distinguish 
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between CE and AE more accurately than serological tests.  Although more research is 
needed to find a more suitable positive control, the specificity and sensitivity of this assay 
would make it possible to diagnose patients in an inexpensive and noninvasive way.  It 
would also make posttreatment monitoring much more accurate as cell-free DNA is 
eliminated from circulation within hours.42 Antibody titers may take several years to 
decrease after successful treatment of AE or CE infection, making the use of serological 
testing unsuitable for posttreatment monitoring.1 When parasitic tissue or extracted DNA 
as well as patient serum samples become available for testing, it could lead to the design 
of a clinical assay that would be of great value to clinicians and those at risk for AE and 
CE infection. 
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